Non-Hodgkin Lymphoma | Specialty

Approval of Acalabrutinib in Mantle Cell Lymphoma

January 26th 2018

Duration of Rituximab Maintenance in FL

January 26th 2018

Long-Term Data With Copanlisib in Follicular Lymphoma

January 26th 2018

Follicular Lymphoma: Obinutuzumab and Chemotherapy

January 26th 2018

MAVORIC Trial in Cutaneous T-Cell Lymphoma

January 26th 2018

Primary Cutaneous T-cell Lymphoma: ALCANZA Trial

January 26th 2018

Role of Novel Therapies in Hodgkin Lymphoma

January 26th 2018

Novel Combinations in Relapsed Hodgkin Lymphoma

January 26th 2018

Hodgkin Lymphoma: Addressing the Elderly Population

January 26th 2018

Hodgkin Lymphoma: Important Findings from CheckMate 205

January 26th 2018

Hodgkin Lymphoma: Using Brentuximab Vedotin Frontline

January 26th 2018

ECHELON-1 Trial: Significance in Hodgkin Lymphoma

January 26th 2018

Novel Antibody Tested in First-Line DLBCL Therapy

January 25th 2018

Investigators are studying the value of polatuzumab vedotin in patients with intermediate- or high-risk diffuse large B-cell lymphoma.

Rituximab Biosimilar Succeeds in Phase III Follicular Lymphoma Trial

January 25th 2018

PF-05280586, a biosimilar for rituximab (Rituxan/MabThera), delivered positive top-line results in the phase III REFLECTIONS B3281006 follicular lymphoma trial.

CHOP-RIT Superior for PFS Versus R-CHOP in High-Risk Follicular Lymphoma

January 23rd 2018

The CHOP-RIT regimen improved progression-free survival compared with R-CHOP alone in previously untreated patients with follicular lymphoma.

Emerging Therapies for Follicular Lymphoma

January 23rd 2018

FL: Updated Data for Immunomodulatory Approaches

January 23rd 2018

Immunomodulatory Therapy for FL: The R-Squared Regimen

January 23rd 2018

Further Considerations for Relapsed/Refractory FL

January 23rd 2018

Treatment Approaches to Relapsed Refractory FL

January 23rd 2018